Publication

Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors

Boiko, A. S., Ivanova, S. A., Pozhidaev, I. V., Freidin, M. B., Osmanova, D. Z., Fedorenko, O. Y., Semke, A. V., Bokhan, N. A., Wilffert, B. & Loonen, A. J. M., 9-Jan-2019, In : The World Journal of Biological Psychiatry. p. 1-6 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Boiko, A. S., Ivanova, S. A., Pozhidaev, I. V., Freidin, M. B., Osmanova, D. Z., Fedorenko, O. Y., ... Loonen, A. J. M. (2019). Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors. The World Journal of Biological Psychiatry, 1-6. https://doi.org/10.1080/15622975.2018.1548780

Author

Boiko, Anastasiia S ; Ivanova, Svetlana A ; Pozhidaev, Ivan V ; Freidin, Maxim B ; Osmanova, Diana Z ; Fedorenko, Olga Yu ; Semke, Arkadyi V ; Bokhan, Nikolay A ; Wilffert, Bob ; Loonen, Anton J M. / Pharmacogenetics of tardive dyskinesia in schizophrenia : The role of CHRM1 and CHRM2 muscarinic receptors. In: The World Journal of Biological Psychiatry. 2019 ; pp. 1-6.

Harvard

Boiko, AS, Ivanova, SA, Pozhidaev, IV, Freidin, MB, Osmanova, DZ, Fedorenko, OY, Semke, AV, Bokhan, NA, Wilffert, B & Loonen, AJM 2019, 'Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors' The World Journal of Biological Psychiatry, pp. 1-6. https://doi.org/10.1080/15622975.2018.1548780

Standard

Pharmacogenetics of tardive dyskinesia in schizophrenia : The role of CHRM1 and CHRM2 muscarinic receptors. / Boiko, Anastasiia S; Ivanova, Svetlana A; Pozhidaev, Ivan V; Freidin, Maxim B; Osmanova, Diana Z; Fedorenko, Olga Yu; Semke, Arkadyi V; Bokhan, Nikolay A; Wilffert, Bob; Loonen, Anton J M.

In: The World Journal of Biological Psychiatry, 09.01.2019, p. 1-6.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Boiko AS, Ivanova SA, Pozhidaev IV, Freidin MB, Osmanova DZ, Fedorenko OY et al. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors. The World Journal of Biological Psychiatry. 2019 Jan 9;1-6. https://doi.org/10.1080/15622975.2018.1548780


BibTeX

@article{96b589ba123f442fa128dd4e2127082a,
title = "Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors",
abstract = "OBJECTIVES: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia (TD). The authors tried to verify this hypothesis by testing for possible associations between two muscarinic receptor genes (CHRM1 and CHRM2) polymorphisms and TD in patients with schizophrenia.METHODS: A total of 472 patients with schizophrenia were recruited. TD was assessed cross-sectionally using the Abnormal Involuntary Movement Scale. Fourteen allelic variants of CHRM1 and CHRM2 were genotyped using Applied Biosystems amplifiers (USA) and the MassARRAY System by Agena Bioscience.RESULTS: The prevalence of the rs1824024*GG genotype of the CHRM2 gene was lower in TD patients compared to the group without it (χ2 = 6.035, p = 0.049). This suggested that this genotype has a protective effect for the development of TD (OR = 0.4, 95{\%} CI: 0.19-0.88). When age, gender, duration of schizophrenia and dosage of antipsychotic treatment were added as covariates in regression analysis, the results did not reach statistical significance.CONCLUSIONS: This study did identify associations between CHRM2 variations and TD; the results of logistic regression analysis with covariates suggest that the association is, however, likely to be secondary to other concomitant factors.",
author = "Boiko, {Anastasiia S} and Ivanova, {Svetlana A} and Pozhidaev, {Ivan V} and Freidin, {Maxim B} and Osmanova, {Diana Z} and Fedorenko, {Olga Yu} and Semke, {Arkadyi V} and Bokhan, {Nikolay A} and Bob Wilffert and Loonen, {Anton J M}",
year = "2019",
month = "1",
day = "9",
doi = "10.1080/15622975.2018.1548780",
language = "English",
pages = "1--6",
journal = "The World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Taylor & Francis Ltd",

}

RIS

TY - JOUR

T1 - Pharmacogenetics of tardive dyskinesia in schizophrenia

T2 - The role of CHRM1 and CHRM2 muscarinic receptors

AU - Boiko, Anastasiia S

AU - Ivanova, Svetlana A

AU - Pozhidaev, Ivan V

AU - Freidin, Maxim B

AU - Osmanova, Diana Z

AU - Fedorenko, Olga Yu

AU - Semke, Arkadyi V

AU - Bokhan, Nikolay A

AU - Wilffert, Bob

AU - Loonen, Anton J M

PY - 2019/1/9

Y1 - 2019/1/9

N2 - OBJECTIVES: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia (TD). The authors tried to verify this hypothesis by testing for possible associations between two muscarinic receptor genes (CHRM1 and CHRM2) polymorphisms and TD in patients with schizophrenia.METHODS: A total of 472 patients with schizophrenia were recruited. TD was assessed cross-sectionally using the Abnormal Involuntary Movement Scale. Fourteen allelic variants of CHRM1 and CHRM2 were genotyped using Applied Biosystems amplifiers (USA) and the MassARRAY System by Agena Bioscience.RESULTS: The prevalence of the rs1824024*GG genotype of the CHRM2 gene was lower in TD patients compared to the group without it (χ2 = 6.035, p = 0.049). This suggested that this genotype has a protective effect for the development of TD (OR = 0.4, 95% CI: 0.19-0.88). When age, gender, duration of schizophrenia and dosage of antipsychotic treatment were added as covariates in regression analysis, the results did not reach statistical significance.CONCLUSIONS: This study did identify associations between CHRM2 variations and TD; the results of logistic regression analysis with covariates suggest that the association is, however, likely to be secondary to other concomitant factors.

AB - OBJECTIVES: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia (TD). The authors tried to verify this hypothesis by testing for possible associations between two muscarinic receptor genes (CHRM1 and CHRM2) polymorphisms and TD in patients with schizophrenia.METHODS: A total of 472 patients with schizophrenia were recruited. TD was assessed cross-sectionally using the Abnormal Involuntary Movement Scale. Fourteen allelic variants of CHRM1 and CHRM2 were genotyped using Applied Biosystems amplifiers (USA) and the MassARRAY System by Agena Bioscience.RESULTS: The prevalence of the rs1824024*GG genotype of the CHRM2 gene was lower in TD patients compared to the group without it (χ2 = 6.035, p = 0.049). This suggested that this genotype has a protective effect for the development of TD (OR = 0.4, 95% CI: 0.19-0.88). When age, gender, duration of schizophrenia and dosage of antipsychotic treatment were added as covariates in regression analysis, the results did not reach statistical significance.CONCLUSIONS: This study did identify associations between CHRM2 variations and TD; the results of logistic regression analysis with covariates suggest that the association is, however, likely to be secondary to other concomitant factors.

U2 - 10.1080/15622975.2018.1548780

DO - 10.1080/15622975.2018.1548780

M3 - Article

SP - 1

EP - 6

JO - The World Journal of Biological Psychiatry

JF - The World Journal of Biological Psychiatry

SN - 1562-2975

ER -

ID: 73873533